0001193125-26-202614
SEC filingJaguar Health received Nasdaq notice of non-compliance with minimum 500,000 publicly held shares requirement post 1-for-35 reverse stock split, serving as additional basis for potential delisting.
Jaguar Health, Inc. faces heightened delisting risk from Nasdaq following a 1-for-35 reverse stock split on April 30, 2026, which reduced publicly held shares to approximately 401,226, breaching Listing Rule 5550(a)(4)'s 500,000 minimum. This deficiency compounds prior issues, including the $1 minimum bid price requirement, and will factor into the Nasdaq Hearings Panel's decision on the Company's Capital Market listing. The Company must respond in writing by May 8, 2026, and demonstrate compliance by achieving a $1.00 closing bid price for at least 10 consecutive business days after curing the shares issue. Staff may extend this period discretionarily. While Jaguar Health states it is working diligently to comply, the filing emphasizes no guarantees of success, exposing shareholders to suspension of trading and transfer to over-the-counter markets, which typically reduces liquidity and visibility for investors.